Family: | Blackrock (iShares) |
Name: | iShares Genomics Immunology and Healthcare ETF |
Inception Date: | 11-Jun-2019 |
Termination Date: | |
Investment Objective: | The iShares Genomics Immunology and Healthcare ETF seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering. |
Prospectus | |
Top 10 Holdings | ||
EXELIXIS INC | EXEL | 6.4910% |
GILEAD SCIENCES INC | GILD | 5.7535% |
INCYTE CORP | INCY | 4.9390% |
BEIGENE LTD | 6160 | 4.9317% |
REVOLUTION MEDICINES INC | RVMD | 4.7258% |
BIONTECH SE ADR | BNTX | 4.6946% |
ROCHE HOLDING PAR AG | ROG | 4.2812% |
SAREPTA THERAPEUTICS INC | SRPT | 4.1418% |
TAKEDA PHARMACEUTICAL LTD | 4502 | 4.0351% |
SANOFI SA | SAN | 3.9393% |
Top 10 Holdings Weight: | 47.9% |
Number of Holdings: | 62 |
Shares Outstanding: | 5,700,000 |
Total Net Assets: | 137,769,600 |
NAV: | 24.24 |
Net Expense Ratio: | 0.47% |
Asset Class: | Equities (Stocks) |
Developed or Emerging: | Developed Market Funds |
Country: | |
Region: | |
Strategy: | |
Currency: | |
Commodity: | |
Sector: | Healthcare |
Industry: | Biotech |
Dividend Type: | |
Tax Exempt State: | |
Maturity Duration: | |
Market Cap: | Broad Market / Multi-Cap |
Credit Quality: | |
Mortgage Bond Types: | |
Bond Type: | |
Gov't Bond Types: | |
Reit Type: | |
Leverage Direction/Factor: | |
Is Currency Hedged: | No |
US or Ex-US: | Global |